{"name":"Grace Therapeutics Inc.","slug":"grace-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"GTX-102 high dose fast Period 1 and Period 2","genericName":"GTX-102 high dose fast Period 1 and Period 2","slug":"gtx-102-high-dose-fast-period-1-and-period-2","indication":"Other","status":"phase_1"},{"name":"GTX-102 medium dose fast Period 1 and Period 2","genericName":"GTX-102 medium dose fast Period 1 and Period 2","slug":"gtx-102-medium-dose-fast-period-1-and-period-2","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CaPre","genericName":"CaPre","slug":"capre","indication":"Hypercholesterolemia","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"GTX-104","genericName":"GTX-104","slug":"gtx-104","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"GTX-102 high dose fast Period 1 and Period 2","genericName":"GTX-102 high dose fast Period 1 and Period 2","slug":"gtx-102-high-dose-fast-period-1-and-period-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CaPre","genericName":"CaPre","slug":"capre","phase":"marketed","mechanism":"CaPre is a prescription medication used to lower cholesterol levels.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"GTX-102 medium dose fast Period 1 and Period 2","genericName":"GTX-102 medium dose fast Period 1 and Period 2","slug":"gtx-102-medium-dose-fast-period-1-and-period-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GTX-104","genericName":"GTX-104","slug":"gtx-104","phase":"phase_3","mechanism":"GTX-104 is a small molecule that targets the PD-1/PD-L1 pathway.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPd0NjM2VCWTJpTkRvWW12ZEdQRHgxcWZ0Ny1XVmwxd3NIS3RObWNmOVVOdW9ERjNmVVhPSkV1NHU2a3ZIVWltSzh1emNUUC1acVFxWncxZ19CRDRLVG1yVlhNdWFuUUpRdVJQSjczMDlOYk5WYkhLTkJzd09ZQ1FHUDVmeHVmWjcxQXNmcG8zMkxuX2djd2ZJSkZQdnlydnhuUzdaVGRqSWYwVjZBaUVXMzBzdw?oc=5","date":"2026-04-07","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Tuesday's Intraday Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9UdHhkQWNrYjRBd0JNOXFYVGJ0SF8xY00zYVlkYlh2NG9qRnRNWTc4S25PczhPNnJ0TGFjbUlscU5ObjRPd1FwbDUwaC1IWHNUbTdnOVBIMG9QLVRocFZVZkFaYV8xQm9mWUs0Z2Fn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Grace Therapeutics, Inc (GRCE) - Stock Titan","headline":"If You Invested $1,000 in Grace Therapeutics, Inc (GRCE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQTjJMcXhIc3JHRzBMcThlakoyM3NVTHlfSlNFUVlBRGI4MEVHNVBpckJJMm5XLUg3Y1dPOWQzeTBHczlCVE80TGdZcURNSnpVaGdYWGwtOFMyM0I3ZjRYa3JtTDdYaTNsTjNBV0l2MlZMV0Z2Z0VNQUxNQUZhSUUwVVM5ejVBQm53Mk1hYk9jYlZIaGFKc05TMkR4YVp1RnBwWGp6aUcyWm5JUloycFA5ZVdSZDA2M09wRW50MFcyN1gzUGxVNVk5SVZ1eXZMb3dJWWpQcW1EdmNaMzJrMFlPWG9WZWNoVWU3S0JnN2VHU3NDU3RsbDF2WWRlQVI5VklhSk90SG1QOA?oc=5","date":"2026-02-13","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: Grace Therapeutics (GRCE), Alto Neuroscience, Inc. (ANRO) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: Grace Therapeutics (GRCE), Alto Neuroscience, Inc. (ANRO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNRll2alRpLTREYTJkSnBxTjdYZkViVmVRUmpLQ3lwMmw4SUtoenZtblhJS09heVpjN2xVemxSUlhUZ0JmTmhlelVJdTRoRDhhTkJsRVJfYWstekp5WUswdExnVTV3ZmtFOEFEdV9FbkxMcVFRMmNMLVEteGJSeHhrcmR6V3duMlEyZm84bzJLRU5pbXpRa2p5LUtaY3dYZDYtX2Rpd3p6dHNleVNqQmxjdEk1dkVybmVnWEpiRw?oc=5","date":"2026-02-12","type":"regulatory","source":"Stock Titan","summary":"April 23 FDA target date set for Grace’s GTx-104 aSAH drug - Stock Titan","headline":"April 23 FDA target date set for Grace’s GTx-104 aSAH drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPNGk3eE5fb2JLZy1kM0l1bnVhMkNmODdxUzlvVUJzVzZ0QWxFRWxsX3ZuRWs0OXdZejRVUG9aVHZCbHYwTnlzZE5LdFczbjJWSFExcUdHdzUxaWFrY0JMN0sxeHZ2ZG9VTVg3NmhvM0s0ZXJZbzlfbVBoZ2ROa3JMNW5jeVRkUXA4b1NXWWFVUVNsY0VXX3FqX1NMZlpKdTBjNmNZc25HTTRWemdYSE8wQ2c0VQ?oc=5","date":"2025-11-13","type":"regulatory","source":"GuruFocus","summary":"Grace Therapeutics (GRCE) Advances with FDA Review of GTx-104 ND - GuruFocus","headline":"Grace Therapeutics (GRCE) Advances with FDA Review of GTx-104 ND","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQTlpSMjd0UzAyUEhWMUhQcExpNEdXQzZ6ZDZrZHFleElpXzRhTy1GMjJTQXA1eUZHQUgzZExQSWlVM25PdnFfSjhBeF9tTERfUnhTZW8zS1ExblRybHJoNms1a3NwU2ZVcWp2MzF1QlNsMURMdzU4QjV3QVJCME9RZXpSWk0xYjFqUGU1ZnVKOVNYd0J6Y1F0TnVLTGNmMGhrdDFNbTFJeWRBSVE5QXlWWTNZbzFHR2tyZHAyUFh0U2Jnc3djeFhyeVlfSUVNR2F3ZUsw?oc=5","date":"2025-08-26","type":"patent","source":"Quiver Quantitative","summary":"Plus Therapeutics, Inc. Confirms Compliance with Nasdaq Listing Rules Ahead of Grace Period Expiration - Quiver Quantitative","headline":"Plus Therapeutics, Inc. Confirms Compliance with Nasdaq Listing Rules Ahead of Grace Period Expiration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOWlRwN19uemZSdThyckVwNnM5VWNPWWk5V2MtZWxjWUdMeGVLd0x3NEgydUllLWVWaVcybGd5N29xMGZGODRqUTg2U1gwRHRKYTNKREhTN0xkUWtwUnMtTzVUaHJFM3pVdmFOWEVJNXpoYWdFOVgwUlI0X2ZrdXM3VGVkSVRaZWs?oc=5","date":"2025-06-24","type":"pipeline","source":"Yahoo Finance","summary":"Grace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near Future - Yahoo Finance","headline":"Grace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near Future","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-10","type":"pipeline","source":"simplywall.st","summary":"Grace Therapeutics, Inc. (NASDAQ:GRCE): When Will It Breakeven? - simplywall.st","headline":"Grace Therapeutics, Inc. (NASDAQ:GRCE): When Will It Breakeven?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9YbFdjZEs2cXNSM0RSSGQ1MnJlMnJ1WFRwbVo1NFRRSjVOODF6cFNaRnJvdlNCN21wLVZkdlBJc2M0cDZuUFNuMXNwdG1PaG1uUTVFRlVRei1ySl84c0FTVDZlZzZiWWpNMkNpV1BxdE1UWXpwNmhCWUZiZW5mZTg?oc=5","date":"2025-04-18","type":"pipeline","source":"INDmoney","summary":"Grace Therapeutics Inc (GRCE) Live Share Price, Invest From India - INDmoney","headline":"Grace Therapeutics Inc (GRCE) Live Share Price, Invest From India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5vaXZvSXlLUHBrNGNzZy11RWJIUzk4UVZreTdFOTNRR2phMDNuRnlReDBBMXh1aVd4WGpFaWhZSUF3R3NtRF9qVjVfSFlDUGZJQl9aTHdvVzI5TFdMZ1o0Z1FMQXRBaFdKbnZZT29jY2pwOXc?oc=5","date":"2025-02-11","type":"pipeline","source":"Pharmaceutical Technology","summary":"Grace to secure $15m to fund GTx-104’s development - Pharmaceutical Technology","headline":"Grace to secure $15m to fund GTx-104’s development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPclo0a0VCVTVHMDBlSWREX2NDVGwzdXlxMHZrZk5rbURUaUY4eG5yVFJJckF5NnNoQnFkdXVZQzU2dzJ2WGtEZ01OT0RFRDdMcm5kVXNDeHBDcjROVk5OdlU1T29kUE5FUlB4cGFoNG8zZWduUnowc1dxR3g3eXBZWEg0d0hMMTV2ajY0a3p3YTNOd2wySVE?oc=5","date":"2025-02-10","type":"pipeline","source":"citybiz","summary":"Grace Therapeutics Announces Financing of $30 Million - citybiz","headline":"Grace Therapeutics Announces Financing of $30 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBNbEQxZ2RqekJrTWxYNmlyYThHd2tZUElLWU8tUVh6TWhMbVpMRDdHVWtoejREemxqZEhUdkRsMzY0emhFajZZY0kwWmVuNXhi?oc=5","date":"2024-10-29","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}